


Stereochemistry abstracts

Antonio García Martínez,* Enrique Teso Vilar, Amelia García Fraile,
Santiago de la Moya Cerero* and Beatriz Lora Maroto

Tetrahedron: Asymmetry 14 (2003) 1959



C₁₄H₂₇NO

10-[(Dimethylamino)methyl]-2-methylisoborneol


[α]_D²⁰ = -18 (c 1.0, CHCl₃)

Source of chirality: natural (+)-(1*R*)-camphor

Absolute configuration: (1*S*,2*R*)

Antonio García Martínez,* Enrique Teso Vilar, Amelia García Fraile,
Santiago de la Moya Cerero* and Beatriz Lora Maroto

Tetrahedron: Asymmetry 14 (2003) 1959



C₁₅H₂₉NO

10-[(Dimethylamino)methyl]-2-ethylisoborneol


[α]_D²⁰ = -13 (c 1.2, CHCl₃)

Source of chirality: natural (+)-(1*R*)-camphor

Absolute configuration: (1*S*,2*R*)

Antonio García Martínez,* Enrique Teso Vilar, Amelia García Fraile,
Santiago de la Moya Cerero* and Beatriz Lora Maroto

Tetrahedron: Asymmetry 14 (2003) 1959



C₁₆H₃₁NO

10-[(Dimethylamino)methyl]-2-isopropylisoborneol


[α]_D²⁰ = -14 (c 2.6, CHCl₃)

Source of chirality: natural (+)-(1*R*)-camphor

Absolute configuration: (1*S*,2*S*)

Antonio García Martínez,* Enrique Teso Vilar, Amelia García Fraile,
Santiago de la Moya Cerero* and Beatriz Lora Maroto

Tetrahedron: Asymmetry 14 (2003) 1959




C₁₇H₃₃NO

2-*tert*-Butyl 10-[(dimethylamino)methyl]isoborneol

[α]_D²⁰ = -19 (c 1.3, CHCl₃)

Source of chirality: natural (+)-(1*R*)-camphor

Absolute configuration: (1*S*,2*S*)




C₁₃H₂₅NO
10-[(Dimethylamino)methyl]isoborneol

[α]_D²⁰ = +7 (c 0.8, CHCl₃)

Source of chirality: natural (+)-(1*R*)-camphor

Absolute configuration: (1*S*,2*R*)




C₂₈H₃₁NO₃
(2*R*,3*R*,4*R*,6*S*)-3,4-Di(benzyloxy)-2-benzyloxymethyl-1-azabicyclo[4.1.0]heptane

[α]_D²⁰ +10.5 (c 1.1, CHCl₃)

Source of chirality: tri-*O*-benzyl-*D*-glucal and stereoselective electrophile-induced cyclization

Absolute configuration: 2*R*,3*R*,4*R*,6*S*




C₃₄H₃₇NO₃S
4,5,7-Tri-*O*-benzyl-2,3,6-trideoxy-2,6-imino-1-*S*-phenyl-1-thio-*D*-manno-heptitol

[α]_D²⁰ +18.0 (c 1.0, CHCl₃)

Source of chirality: tri-*O*-benzyl-*D*-glucal and stereoselective electrophile-induced cyclization

Absolute configuration: 2*S*,4*R*,5*R*,6*R*





C₃₂H₄₀N₂O₄
4,5,7-Tri-*O*-benzyl-1,2,3,6-tetradeoxy-2,6-imino-1-morpholino-*D*-manno-heptitol

[α]_D²⁰ +22.5 (c 0.6, CHCl₃)

Source of chirality: tri-*O*-benzyl-*D*-glucal and stereoselective electrophile-induced cyclization

Absolute configuration: 2*S*,4*R*,5*R*,6*R*




4,5,7-Tri-O-benzyl-1,2,3,6-tetrahydroxy-1-diallylamino-2,6-imino-D-manno-heptitol

[α]_D²⁰ +9.5 (*c* 0.2, CHCl₃)

Source of chirality: tri-O-benzyl-D-glucal and stereoselective electrophile-induced cyclization

Absolute configuration: 2S,4R,5R,6R





4,5,7-Tri-O-benzyl-1-O-butanoyl-2,3,6-trideoxy-2,6-imino-D-manno-heptitol

[α]_D²⁰ +19.5 (*c* 0.9, CHCl₃)

Source of chirality: tri-O-benzyl-D-glucal and stereoselective electrophile-induced cyclization

Absolute configuration: 2S,4R,5R,6R




1-O-Benzoyl-4,5,7-tri-O-benzyl-2,3,6-trideoxy-2,6-imino-D-manno-heptitol

[α]_D²⁰ +25.5 (*c* 0.5, CHCl₃)

Source of chirality: tri-O-benzyl-D-glucal and stereoselective electrophile-induced cyclization

Absolute configuration: 2S,4R,5R,6R




4,5,7-Tri-O-benzyl-1-O-(benzyloxycarbonylaminoacetyl)-2,3,6-trideoxy-2,6-imino-D-manno-heptitol

[α]_D²⁰ +20.5 (*c* 1.2, CHCl₃)

Source of chirality: tri-O-benzyl-D-glucal and stereoselective electrophile-induced cyclization

Absolute configuration: 2S,4R,5R,6R




C₄₂H₄₆NO₇P

4,5,7-Tri-O-benzyl-1-O-(dibenzylxyphosphoryl)-2,3,6-trideoxy-2,6-imino-D-manno-heptitol

[α]_D²⁰ +13.5 (*c* 1.9, CHCl₃)

Source of chirality: tri-O-benzyl-D-glucal and stereoselective electrophile-induced cyclization

Absolute configuration: 2S,4R,5R,6R




C₂₉H₃₅NO₃

(2R,3R,4R,6R)-3,4-Di(benzyloxy)-2-benzyloxymethyl-6-ethylpiperidine

[α]_D²⁰ +24.0 (*c* 1.4, CHCl₃)

Source of chirality: tri-O-benzyl-D-glucal and stereoselective electrophile-induced cyclization

Absolute configuration: 2R,3R,4R,6R




C₈H₁₇NO₃

(2R,3R,4R,6R)-2-Hydroxymethyl-6-ethylpiperidine-3,4-diol- (α-1-C-ethyl-fagomine)

[α]_D²⁰ +42.5 (*c* 0.4, H₂O)

Source of chirality: tri-O-benzyl-D-glucal and stereoselective electrophile-induced cyclization

Absolute configuration: 2R,3R,4R,6R




C₇H₁₃NO₃

(2R,3R,4R,6S)-2-Hydroxymethyl-1-azabicyclo[4.1.0]heptane-3,4-diol


[α]_D²⁰ +57.7 (*c* 0.4, H₂O)

Source of chirality: tri-O-benzyl-D-glucal and stereoselective electrophile-induced cyclization


Absolute configuration: 2R,3R,4R,6S

 $C_{30}H_{32}N_2$ *N,N'*-Bis(2-ethylphenyl)-6,6'-dimethylbiphenyl-2,2'-diamine


E.e.=99.5% [by HPLC analysis of a precursor]

 $[\alpha]_D^{24.2}=-147$ (*c* 0.20, CHCl₃)Source of chirality: (*R*)(+)-2,2'-diamino-6,6'-dimethylbiphenylAbsolute configuration: *R* $C_{38}H_{44}N_2$ *N,N'*-Bis(2-cyclohexylphenyl)-6,6'-dimethylbiphenyl-2,2'-diamine

E.e.=99.5% [by HPLC analysis of a precursor]

 $[\alpha]_D^{24.5}=-152$ (*c* 0.20, CHCl₃)Source of chirality: (*R*)(+)-2,2'-diamino-6,6'-dimethylbiphenylAbsolute configuration: *R* $C_{36}H_{44}N_2$ *N,N'*-Bis(2-methyl-5-tert-butylphenyl)-6,6'-dimethylbiphenyl-2,2'-diamine

E.e.=99.5% [by HPLC analysis of a precursor]

 $[\alpha]_D^{24.7}=-158$ (*c* 0.20, CHCl₃)Source of chirality: (*R*)(+)-2,2'-diamino-6,6'-dimethylbiphenylAbsolute configuration: *R* $C_{21}H_{24}N_2O_4S$ *N*-[*N'*-Tosyl-(2*S*)-prolyl]-3*R*-2,3-dihydro-3-methyl-4*H*-1,4-benzoxazine

D.e.=99.2% (by HPLC)


 $[\alpha]_D^{20}-330$ (*c* 1.1, CHCl₃)

Source of chirality: resolution

Absolute configuration: (2*S*,3'*R*)

Victor P. Krasnov,* Galina L. Levit, Iraida M. Bukrina,
Irina N. Andreeva, Liliya Sh. Sadretdinova, Marina A. Korolyova,
Mikhail I. Kodess, Valery N. Charushin and Oleg N. Chupakhin

Tetrahedron: Asymmetry 14 (2003) 1985



C₂₂H₂₆N₂O₃S

N-[*N'*-Tosyl-(2*S*)-prolyl]-(*2R*)-2-methyl-1,2,3,4-tetrahydroquinoline

D.e.=99.0% (by HPLC)


[α]_D²⁰ -372 (*c* 2.0, CHCl₃)

Source of chirality: resolution

Absolute configuration: (2*S*,2'*R*)

Victor P. Krasnov,* Galina L. Levit, Iraida M. Bukrina,
Irina N. Andreeva, Liliya Sh. Sadretdinova, Marina A. Korolyova,
Mikhail I. Kodess, Valery N. Charushin and Oleg N. Chupakhin

Tetrahedron: Asymmetry 14 (2003) 1985



C₂₁H₂₄N₂O₃S

N-[*N'*-Tosyl-(2*S*)-prolyl]-(*2R*)-2-methylindoline

D.e.=98.8% (by HPLC)


[α]_D²⁰ -78 (*c* 1.1, CHCl₃)

Source of chirality: resolution

Absolute configuration: (2*S*,2'*R*)

Victor P. Krasnov,* Galina L. Levit, Iraida M. Bukrina,
Irina N. Andreeva, Liliya Sh. Sadretdinova, Marina A. Korolyova,
Mikhail I. Kodess, Valery N. Charushin and Oleg N. Chupakhin

Tetrahedron: Asymmetry 14 (2003) 1985



C₉H₁₁NO

(-)-(*R*)-2,3-Dihydro-3-methyl-4*H*-1,4-benzoxazine

E.e.=97.0% (by HPLC)


[α]_D²⁰ -19 (*c* 1.3, CHCl₃)

Source of chirality: resolution

Absolute configuration: (*R*)

Victor P. Krasnov,* Galina L. Levit, Iraida M. Bukrina,
Irina N. Andreeva, Liliya Sh. Sadretdinova, Marina A. Korolyova,
Mikhail I. Kodess, Valery N. Charushin and Oleg N. Chupakhin

Tetrahedron: Asymmetry 14 (2003) 1985



C₁₀H₁₃N

(+)-(*R*)-2-Methyl-1,2,3,4-tetrahydroquinoline

E.e.=96.7% (by HPLC)


[α]_D²⁰ +84 (*c* 1.3, benzene)

Source of chirality: resolution

Absolute configuration: (*R*)

Victor P. Krasnov,* Galina L. Levit, Iraida M. Bukrina,
Irina N. Andreeva, Liliya Sh. Sadretdinova, Marina A. Korolyova,
Mikhail I. Kodess, Valery N. Charushin and Oleg N. Chupakhin

Tetrahedron: Asymmetry 14 (2003) 1985



C₉H₁₁NO
(+)-(R)-2-Methylindoline

E.e. = 97.2% (by HPLC)


[α]_D²⁰ +11 (*c* 2.0, benzene)

Source of chirality: resolution

Absolute configuration: (*R*)

Christabel Carter, Sarah Fletcher and Adam Nelson*

Tetrahedron: Asymmetry 14 (2003) 1995



C₄₄H₃₆BNO₄
Diethylammonium bis[(*R*)-1,1'-bi-2-naphtholato]borate


E.e. >98%

[α]_D = -265.3 (*c* 1.10, DMSO)

Source of chirality: (*R*)-1,1'-bi-2-naphthol

Christabel Carter, Sarah Fletcher and Adam Nelson*

Tetrahedron: Asymmetry 14 (2003) 1995



C₄₆H₄₀BNO₄
Triethylammonium bis[(*R*)-1,1'-bi-2-naphtholato] borate


E.e. >98%

[α]_D = -232.4 (*c* 1.01, DMSO)

Source of chirality: (*R*)-1,1'-bi-2-naphthol

Christabel Carter, Sarah Fletcher and Adam Nelson*

Tetrahedron: Asymmetry 14 (2003) 1995




C₄₈H₃₆BNO₄
(*R*)- α -Methylbenzylammonium bis[(*S*)-1,1'-bi-2-naphtholato]borate

E.e. >98%


[α]_D = 320.9 (*c* 1.05, DMSO)

Source of chirality: (*S*)-1,1'-bi-2-naphthol and
(*R*)- α -methylbenzylamine



$C_{40}H_{24}BNaO_4$
Sodium bis[(*R*)-1,1'-bi-2-naphtholato]borate


E.e. >98%

 $[\alpha]_D^{25} = +173.6$ (*c* 1.04, DMSO)Source of chirality: (*R*)-1,1'-bi-2-naphthol

$C_{14}H_{16}INO_4$
(2*S*,5*R*)-2-Benzylxycarbonylamino-5-iodomethyl- δ -valerolactone

 $[\alpha]_D^{25} = +7.0$ (*c* 1, CHCl₃)


Source of chirality: asymmetric synthesis

Absolute configuration: (2*S*,5*R*)

$C_{14}H_{16}INO_4$
(2*S*,5*S*)-2-Benzylxycarbonylamino-5-iodomethyl- δ -valerolactone

 $[\alpha]_D^{25} = +41.5$ (*c* 1, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (2*S*,5*S*)


$C_{14}H_{17}NO_4$
(*S*)-2-Benzylxycarbonylaminohex-5-enoic acid

Ee >98%

 $[\alpha]_D^{25} = +21.6$ (*c* 1, CHCl₃)

Source of chirality: asymmetric synthesis



Absolute configuration: (2*S*)

Allyl (2*S*)-2-benzyloxycarbonylamino-6-iodo-5-oxohexanoate $[\alpha]_D^{25} = -3.0$ (*c* 1, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (2*S*)Tatyana I. Danilova, Valeria I. Rozenberg,* Elena V. Sergeeva,
Zoya A. Starikova and Stefan Bräse*

Tetrahedron: Asymmetry 14 (2003) 2013

Schiff base of (*S*)-4-formyl-5-hydroxy[2.2]paracyclophane and ethanolamine



E.e. >99%

 $[\alpha]_D^{22} -481.8$ (*c* 0.23, CHCl₃)

Source of chirality: chiral starting material

Absolute configuration: (*Sp*)Tatyana I. Danilova, Valeria I. Rozenberg,* Elena V. Sergeeva,
Zoya A. Starikova and Stefan Bräse*

Tetrahedron: Asymmetry 14 (2003) 2013

Schiff base of (*R*)-4-formyl-5-hydroxy[2.2]paracyclophane and (*R*)-valinol



E.e. >98%

 $[\alpha]_D^{22} +653.5$ (*c* 0.36, CH₃OH)

Source of chirality: chiral starting material

Absolute configuration: (*Rp,R*)Tatyana I. Danilova, Valeria I. Rozenberg,* Elena V. Sergeeva,
Zoya A. Starikova and Stefan Bräse*

Tetrahedron: Asymmetry 14 (2003) 2013

Schiff base of (*R*)-4-acetyl-5-hydroxy[2.2]paracyclophane and ethanolamine

E.e. >99%


 $[\alpha]_D^{22} +611.7$ (*c* 0.21, CHCl₃)

Source of chirality: chiral starting material

Absolute configuration: (*Rp*)

Tatyana I. Danilova, Valeria I. Rozenberg,* Elena V. Sergeeva,
Zoya A. Starikova and Stefan Bräse*

Tetrahedron: Asymmetry 14 (2003) 2013



Schiff base of (*R*)-4-acetyl-5-hydroxy[2.2]paracyclophane and (*S*)-valinol

E.e. >99%


$[\alpha]_D^{22} 653.5$ (*c* 0.25, CHCl₃)

Source of chirality: chiral starting material

Absolute configuration: (*Rp,S*)

Tatyana I. Danilova, Valeria I. Rozenberg,* Elena V. Sergeeva,
Zoya A. Starikova and Stefan Bräse*

Tetrahedron: Asymmetry 14 (2003) 2013



Schiff base of (*S*)-4-acetyl-5-hydroxy[2.2]paracyclophane and (*S*)-valinol

E.e. >99%


$[\alpha]_D^{22} -603.8$ (*c* 0.27, CHCl₃)

Source of chirality: chiral starting material

Absolute configuration: (*Sp,S*)

Tatyana I. Danilova, Valeria I. Rozenberg,* Elena V. Sergeeva,
Zoya A. Starikova and Stefan Bräse*

Tetrahedron: Asymmetry 14 (2003) 2013



Schiff base of (*S*)-4-acetyl-5-hydroxy[2.2]paracyclophane and (*S*)-leucinol

E.e. >99%


$[\alpha]_D^{22} -560.8$ (*c* 0.22, CHCl₃)

Source of chirality: chiral starting material

Absolute configuration: (*Sp,S*)

Tatyana I. Danilova, Valeria I. Rozenberg,* Elena V. Sergeeva,
Zoya A. Starikova and Stefan Bräse*

Tetrahedron: Asymmetry 14 (2003) 2013



Schiff base of (*R*)-4-acetyl-5-hydroxy[2.2]paracyclophane and (*S*)-leucinol

E.e. >99%


$[\alpha]_D^{22} +646.8$ (*c* 0.24, CHCl₃)

Source of chirality: chiral starting material

Absolute configuration: (*Rp,S*)

Felix Busqué, Mariona Cantó, Pedro de March,* Marta Figueredo, Josep Font and Sonia Rodríguez

Tetrahedron: Asymmetry 14 (2003) 2021



(+)-(2*R*,*3R*)-2,3-Diphenyl-1,4-dioxaspiro[4.5]decan-8-one

Ee = 100%


$[\alpha]_D^{20} = +38.4$ (*c* 1.3, CHCl₃)

Source of chirality: (*R,R*)-1,2-diphenyl ethanediol

Absolute configuration: (2*R*,*3R*)

Felix Busqué, Mariona Cantó, Pedro de March,* Marta Figueredo, Josep Font and Sonia Rodríguez

Tetrahedron: Asymmetry 14 (2003) 2021



(+)-(2*R*,*3R*)-8,8-Diethoxy-2,3-diphenyl-1,4-dioxaspiro[4.5]decane

Ee = 100%


$[\alpha]_D^{20} = +18.5$ (*c* 0.3, CHCl₃)

Source of chirality: (*R,R*)-1,2-diphenyl ethanediol

Absolute configuration: (2*R*,*3R*)

Felix Busqué, Mariona Cantó, Pedro de March,* Marta Figueredo, Josep Font and Sonia Rodríguez

Tetrahedron: Asymmetry 14 (2003) 2021



(+)-4-[(1*R*,2*R*)-2-Hydroxy-1,2-diphenylethoxy]phenol

Ee = 100%


$[\alpha]_D^{20} = +13.3$ (*c* 0.5, acetone)

Source of chirality: (*R,R*)-1,2-diphenyl ethanediol

Absolute configuration: (1*R*,2*R*)

Núria Casamitjana, Mercedes Amat, Núria Llor, Marçal Carreras, Xavier Pujol, M. Montserrat Fernández, Virgina López, Elies Molins, Carles Miravittles and Joan Bosch*

Tetrahedron: Asymmetry 14 (2003) 2033



(3*R*,5*aR*,9*aS*,10*aS*)-5*a*-(Methoxycarbonyl)-7,8-dimethyl-5-oxo-3-phenyl-2,3,9,9*a*,10,10*a*-hexahydro-6*H*-oxazolo[3,2-*b*]isoquinoline


$[\alpha]_D^{22} = -13.0$ (*c* 1.15, CHCl₃)

Source of chirality: (*R*)-(-)-phenylglycinol

Absolute configuration: 3*R*,5*aR*,9*aS*,10*aS* (determined by X-ray crystallography)

Núria Casamitjana, Mercedes Amat, Núria Llor, Marçal Carreras, Xavier Pujol, M. Montserrat Fernández, Virgina López, Elies Molins, Carles Miravittles and Joan Bosch*

Tetrahedron: Asymmetry 14 (2003) 2033



(3*R*,5*aR*,9*aS*,10*aS*)-5*a*-(Methoxycarbonyl)-8-methyl-5-oxo-3-phenyl-2,3,9,9*a*,10,10*a*-hexahydro-6*H*-oxazolo[3,2-*b*]isoquinoline

$[\alpha]_D^{22} = -15.3$ (*c* 1.08, CHCl₃)

Source of chirality: (*R*)-(-)-phenylglycinol

Absolute configuration: 3*R*,5*aR*,9*aS*,10*aS*

Núria Casamitjana, Mercedes Amat, Núria Llor, Marçal Carreras, Xavier Pujol, M. Montserrat Fernández, Virgina López, Elies Molins, Carles Miravittles and Joan Bosch*

Tetrahedron: Asymmetry 14 (2003) 2033



(3*R*,5*aR*,9*aR*,10*aS*)-5*a*-(Methoxycarbonyl)-5,8-dioxo-3-phenyl-2,3,9,9*a*,10,10*a*-hexahydro-8*H*-oxazolo[3,2-*b*]isoquinoline


$[\alpha]_D^{22} = +3.1$ (*c* 0.32, EtOH)

Source of chirality: (*R*)-(-)-phenylglycinol

Absolute configuration: 3*R*,5*aS*,9*aR*,10*aS*

Núria Casamitjana, Mercedes Amat, Núria Llor, Marçal Carreras, Xavier Pujol, M. Montserrat Fernández, Virgina López, Elies Molins, Carles Miravittles and Joan Bosch*

Tetrahedron: Asymmetry 14 (2003) 2033



(3*R*,8*aS*)-5-Oxo-3-phenyl-6,6-bis(phenylsulfanyl)-2,3,6,7,8,8*a*-hexahydro-5*H*-oxazolo[3,2-*a*]pyridine


$[\alpha]_D^{22} = -49.0$ (*c* 0.5, CHCl₃)

Source of chirality: (*R*)-(-)-phenylglycinol

Absolute configuration: 3*R*,8*aS*

Núria Casamitjana, Mercedes Amat, Núria Llor, Marçal Carreras, Xavier Pujol, M. Montserrat Fernández, Virgina López, Elies Molins, Carles Miravittles and Joan Bosch*

Tetrahedron: Asymmetry 14 (2003) 2033



(3*R*,5*aR*,9*aS*,10*aS*)-5*a*-(Benzenesulfonyl)-7,8-dimethyl-5-oxo-3-phenyl-2,3,9,9*a*,10,10*a*-hexahydro-6*H*-oxazolo[3,2-*b*]isoquinoline


$[\alpha]_D^{22} = -5.5$ (*c* 0.3, EtOH)

Source of chirality: (*R*)-(-)-phenylglycinol

Absolute configuration: 3*R*,5*aR*,9*aS*,10*aS*

Núria Casamitjana, Mercedes Amat, Núria Llor, Marçal Carreras, Xavier Pujol, M. Montserrat Fernández, Virgina López, Elies Molins, Carles Miravittles and Joan Bosch*

Tetrahedron: Asymmetry 14 (2003) 2033



(3*R*,5*aS*,9*aR*,10*aR*)-5*a*-(Methoxycarbonyl)-7,8-dimethyl-5-oxo-3-phenyl-2,3,9,9*a*,10,10*a*-hexahydro-6*H*-oxazolo[3,2-*b*]isoquinoline


[α]_D²² = -131.3 (*c* 0.6, MeOH)

Source of chirality: (*R*)-(-)-phenylglycinol

Absolute configuration: 3*R*,5*aS*,9*aR*,10*aR* (determined by X-ray crystallography)

Núria Casamitjana, Mercedes Amat, Núria Llor, Marçal Carreras, Xavier Pujol, M. Montserrat Fernández, Virgina López, Elies Molins, Carles Miravittles and Joan Bosch*

Tetrahedron: Asymmetry 14 (2003) 2033



(3*R*,5*aR*,9*aS*,10*aR*)-5*a*-(Methoxycarbonyl)-7,8-dimethyl-5-oxo-3-phenyl-2,3,9,9*a*,10,10*a*-hexahydro-6*H*-oxazolo[3,2-*b*]isoquinoline


[α]_D²² = +34.7 (*c* 0.76, MeOH)

Source of chirality: (*R*)-(-)-phenylglycinol

Absolute configuration: 3*R*,5*aR*,9*aS*,10*aR*

Núria Casamitjana, Mercedes Amat, Núria Llor, Marçal Carreras, Xavier Pujol, M. Montserrat Fernández, Virgina López, Elies Molins, Carles Miravittles and Joan Bosch*

Tetrahedron: Asymmetry 14 (2003) 2033



(3*R*,5*aS*,9*aR*,10*aS*)-5*a*-(Methoxycarbonyl)-7,8-dimethyl-5-oxo-3-phenyl-2,3,9,9*a*,10,10*a*-hexahydro-6*H*-oxazolo[3,2-*b*]isoquinoline


[α]_D²² = -2.2 (*c* 0.98, MeOH)

Source of chirality: (*R*)-(-)-phenylglycinol

Absolute configuration: 3*R*,5*aS*,9*aR*,10*aS*

Núria Casamitjana, Mercedes Amat, Núria Llor, Marçal Carreras, Xavier Pujol, M. Montserrat Fernández, Virgina López, Elies Molins, Carles Miravittles and Joan Bosch*

Tetrahedron: Asymmetry 14 (2003) 2033



(4*aR*,8*aS*)-8*a*-(Hydroxymethyl)-2-[(1*R*)-2-hydroxy-1-phenylethyl]-6,7-dimethyl-2,3,4,4*a*,5,8-hexahydro-1*H*-isoquinoline



[α]_D²² = -4.6 (*c* 0.2, MeOH)

Source of chirality: (*R*)-(-)-phenylglycinol

Absolute configuration: 4*aR*,8*aS*

Núria Casamitjana, Mercedes Amat, Núria Llor, Marçal Carreras, Xavier Pujol, M. Montserrat Fernández, Virgina López, Elies Molins, Carles Miravittles and Joan Bosch*

Tetrahedron: Asymmetry 14 (2003) 2033



(4aS,8aR)-8a-(Hydroxymethyl)-2-[(1R)-2-hydroxy-1-phenylethyl]-6,7-dimethyl-2,3,4,4a,5,8-hexahydro-1H-isoquinoline



$[\alpha]_D^{22} = -4.5$ (*c* 0.25, MeOH)

Source of chirality: (*R*)-(−)-phenylglycinol

Absolute configuration: 4aS,8aR

Núria Casamitjana, Mercedes Amat, Núria Llor, Marçal Carreras, Xavier Pujol, M. Montserrat Fernández, Virgina López, Elies Molins, Carles Miravittles and Joan Bosch*

Tetrahedron: Asymmetry 14 (2003) 2033



(4aR,8aS)-2-(tert-Butoxycarbonyl)-8a-(hydroxymethyl)-6,7-dimethyl-3,4,4a,5,8,8a-hexahydro-1H-isoquinoline



$[\alpha]_D^{22} = +5.0$ (*c* 2.0, MeOH)

Source of chirality: (*R*)-(−)-phenylglycinol

Absolute configuration: 4aR,8aS

Núria Casamitjana, Mercedes Amat, Núria Llor, Marçal Carreras, Xavier Pujol, M. Montserrat Fernández, Virgina López, Elies Molins, Carles Miravittles and Joan Bosch*

Tetrahedron: Asymmetry 14 (2003) 2033



(4aS,8aR)-2-(tert-Butoxycarbonyl)-8a-(hydroxymethyl)-6,7-dimethyl-3,4,4a,5,8,8a-hexahydro-1H-isoquinoline


$[\alpha]_D^{22} = -5.5$ (*c* 2.0, MeOH)

Source of chirality: (*R*)-(−)-phenylglycinol

Absolute configuration: 4aS,8aR

Francesco Molinari,* Raffaella Gandolfi, Raffaella Villa, Eva Urban and Andreas Kiener

Tetrahedron: Asymmetry 14 (2003) 2041




Methyl 2-methyl-3-hydroxypropionate

E.e. = 97%

$[\alpha]_D^{20} = -25.6$ (*c* 2.0, MeOH)

Source of chirality: enzymatic reaction

Absolute configuration: *R*


 $C_{21}H_{29}N_2P$

(2S)-(-)-1-(2-N,N-Dimethylamino)ethyl-2-(diphenylphosphinomethyl)-pyrrolidine

E.e. $\geq 99\%$ $[\alpha]_D^{25} = -160.0$ (*c* 1.18, EtOH)

Source of chirality: (S)-prolinol

Absolute configuration: 2S


 $C_{23}H_{33}N_2P$

(2S)-(-)-1-(2-N,N-Diethylamino)ethyl-2-(diphenylphosphinomethyl)-pyrrolidine

E.e. $\geq 99\%$ $[\alpha]_D^{25} = -83.1$ (*c* 1.09, EtOH)

Source of chirality: (S)-prolinol

Absolute configuration: 2S


 $C_{26}H_{31}N_2P$

(2S)-(-)-1-(2-N-Methyl, N-phenylamino)ethyl-2-(diphenylphosphinomethyl)-pyrrolidine

E.e. $\geq 99\%$ $[\alpha]_D^{25} = -144.5$ (*c* 1.05, EtOH)

Source of chirality: (S)-prolinol

Absolute configuration: 2S


 $C_{31}H_{33}N_2P$

(2S)-(-)-1-(2-N,N-Diphenylamino)ethyl-2-(diphenylphosphinomethyl)-pyrrolidine

E.e. $\geq 99\%$ $[\alpha]_D^{25} = -102.1$ (*c* 1.05, EtOH)

Source of chirality: (S)-prolinol

Absolute configuration: 2S




C₂₈H₂₈NP
(2S)-(-)-1-(1-Naphthylmethyl)-2-[(diphenylphosphino)methyl]-pyrrolidine

E.e. ≥99%

[α]_D²⁵ = -154.8 (*c* 1.08, EtOH)

Source of chirality: (S)-prolinol

Absolute configuration: 2S




C₂₂H₃₀NP
(2S)-(-)-1-(2,2-Dimethylpropyl)-2-[(diphenylphosphino)methyl]-pyrrolidine

E.e. ≥99%

[α]_D²⁵ = -152.1 (*c* 1.01, EtOH)

Source of chirality: (S)-prolinol

Absolute configuration: 2S




C₂₂H₂₈NOP
(2S)-(-)-1-(2,2-Dimethylpropionyl)-2-[(diphenylphosphino)methyl]-pyrrolidine

E.e. ≥99%

[α]_D²⁵ = -71.6 (*c* 1.70, EtOH)

Source of chirality: (S)-prolinol

Absolute configuration: 2S







C₃₁H₃₁N₂OP
(2S)-1-[2-(N,N-Diphenylamino)]acetyl-2-[(diphenylphosphino)methyl]-pyrrolidine


E.e. ≥99%

[α]_D²⁵ = -67.8 (*c* 1.06, EtOH)

Source of chirality: (S)-prolinol

Absolute configuration: 2S

 $C_{21}H_{27}N_2OP$ (2*S*)-1-[2-(*N,N*-Dimethylamino)]acetyl-2-(diphenylphosphinomethyl)-pyrrolidineE.e. $\geq 99\%$ $[\alpha]_D^{25} = -94.5$ (*c* 1.24, EtOH)Source of chirality: (*S*)-prolinolAbsolute configuration: 2*S* $C_{24}H_{33}N_2OP$ (2'*S*,*S*)-(-)-1-[2-(*N,N*-Dimethylamino)-3-methyl]-butyryl-2-(diphenylphosphinomethyl)-pyrrolidineE.e. $\geq 99\%$ $[\alpha]_D^{25} = -78.8$ (*c* 1.24, EtOH)Source of chirality: (*S*)-prolinol and L-valineAbsolute configuration: 2*S*,2'*S* $C_{28}H_{35}N_2P$ (2'*S*,*S*)-1-[2-(*N,N*-Dimethylamino)-3-phenyl]-2-(diphenylphosphinomethyl)pyrrolidineE.e. $\geq 99\%$ $[\alpha]_D^{25} = -83.1$ (*c* 1.09, EtOH)Source of chirality: (*S*)-prolinol and D-phenylalanineAbsolute configuration: 2*S*,2'*S* $C_{28}H_{35}N_2P$ (2'*R*,*S*)-(-)-1-[2-(*N,N*-Dimethylamino)-3-phenyl]-2-(diphenylphosphinomethyl)pyrrolidineE.e. $\geq 99\%$ $[\alpha]_D^{25} = -160.0$ (*c* 1.18, EtOH)Source of chirality: (*S*)-prolinol and L-phenylalanineAbsolute configuration: 2*S*,2'*R*




C₂₄H₃₅N₂P
(2'S,2S)-(-)-1-[2-(N,N-Dimethylamino)-3-methyl]butyl-2-(diphenylphosphinomethyl)pyrrolidine

E.e. ≥99%

[α]_D²⁵ = -132.6 (*c* 1.08, EtOH)

Source of chirality: (S)-prolinol and L-valine

Absolute configuration: 2S,2'S




Ethyl (1R,2S)-2-hydroxycyclopentanecarboxylate

E.e. >99% by chiral GC

[α]_D²⁰ +22.1 (*c* 1.0, MeOH)

Source of chirality: enzymatic resolution

Absolute configuration: 1R,2S




Ethyl (1S,2S)-2-hydroxycyclopentanecarboxylate

E.e. >99% by chiral HPLC

[α]_D²⁰ +50.3 (*c* 1.3, Et₂O)

Source of chirality: enzymatic resolution

Absolute configuration: 1S,2S




Ethyl (1R,2R)-2-acetoxyxyclopentanecarboxylate

E.e. >99% by chiral HPLC

[α]_D²⁰ -53.0 (*c* 1.3, CHCl₃)

Source of chirality: enzymatic resolution


Absolute configuration: 1R,2R

Ethyl (1*S*,2*R*)-2-acetoxyxyclopentanecarboxylate

E.e. >99% by chiral GC

 $[\alpha]_D^{20} -8.0$ (*c* 0.8, CHCl₃)


Source of chirality: enzymatic resolution

Absolute configuration: 1*S*,2*R*Ethyl (1*S*,2*S*)-2-hydroxycyclohexanecarboxylate

E.e. >99% by chiral GC

 $[\alpha]_D^{20} +40.1$ (*c* 1.0, CHCl₃)


Source of chirality: enzymatic resolution

Absolute configuration: 1*S*,2*S*Ethyl (1*S*,2*R*)-2-acetoxyxycyclohexanecarboxylate

E.e. >99% by chiral GC

 $[\alpha]_D^{20} -24.2$ (*c* 1.1, CHCl₃)

Source of chirality: enzymatic resolution


Absolute configuration: 1*S*,2*R*Ethyl (1*R*,2*S*)-2-hydroxycyclohexanecarboxylate

E.e. >99% by chiral GC

 $[\alpha]_D^{20} +18.2$ (*c* 2.3, CHCl₃)

Source of chirality: enzymatic resolution


Absolute configuration: 1*R*,2*S*

Ethyl (1*R*,2*R*)-2-acetoxyxyclohexanecarboxylate

E.e. >99% by chiral GC

 $[\alpha]_D^{20} -53.0$ (*c* 1.3, CHCl₃)


Source of chirality: enzymatic resolution

Absolute configuration: 1*R*,2*R*Methyl (1*R*,2*S*)-2-hydroxycycloheptanecarboxylate

E.e. >99% by chiral HPLC

 $[\alpha]_D^{20} +43.2$ (*c* 1.2, CHCl₃)


Source of chirality: enzymatic resolution

Absolute configuration: 1*R*,2*S*Methyl (1*S*,2*S*)-2-hydroxycycloheptanecarboxylate

E.e. >99% by chiral GC

 $[\alpha]_D^{20} +8.1$ (*c* 1.9, CHCl₃)

Source of chirality: enzymatic resolution


Absolute configuration: 1*S*,2*S*Methyl (1*S*,2*R*)-2-acetoxyxycycloheptanecarboxylate

E.e. >99% by chiral HPLC

 $[\alpha]_D^{20} +10.5$ (*c* 1.4, CHCl₃)

Source of chirality: enzymatic resolution


Absolute configuration: 1*S*,2*R*

Methyl (1*R*,2*R*)-2-hydroxycycloheptanecarboxylate

E.e. >99% by chiral GC

 $[\alpha]_D^{20} -13.4$ (*c* 2.4, CHCl₃)


Source of chirality: enzymatic resolution

Absolute configuration: 1*R*,2*R*Ethyl (1*S*,2*S*)-2-hydroxycycloheptanecarboxylate

E.e. >99% by chiral GC

 $[\alpha]_D^{20} +17.3$ (*c* 0.7, CHCl₃)


Source of chirality: enzymatic resolution

Absolute configuration: 1*S*,2*S*Ethyl (1*R*,2*S*)-2-hydroxycycloheptanecarboxylate

E.e. >99% by chiral HPLC

 $[\alpha]_D^{20} +48.7$ (*c* 0.9, CHCl₃)

Source of chirality: enzymatic resolution

Absolute configuration: 1*R*,2*S*


4-Ethyl 1-methyl 3-(4-methoxy-phenylamino)-2,2-dimethylsuccinate

Ee = 90% by HPLC on Chiracel® OD-H column

 $[\alpha]_D^{20} = -20.1$ (*c* 0.84, CHCl₃)

Source of chirality: asymmetric catalysis

Absolute configuration: not known




(R)-N-(Dimethylaminomethylene)-1-[(S)-2-(diphenylphosphino)ferrocenyl]ethylamine

E.e. >98%

[α]_D²⁵ = -427 (c 0.11, CHCl₃)

Source of chirality: (R)-1-[(S)-2-(diphenylphosphino)ferrocenyl]ethylamine

Absolute configuration: central chirality: R,
planar chirality: S




(R)-N-(Dimethylaminomethylene)-1-[(S)-2-(diphenylphosphino)ferrocenyl]propylamine

E.e. >98%

[α]_D²⁵ = -450 (c 0.22, CHCl₃)

Source of chirality: (R)-1-[(S)-2-(diphenylphosphino)ferrocenyl]propylamine

Absolute configuration: central chirality: R,
planar chirality: S




(R)-N-(Dimethylaminomethylene)-1-[(S)-2-(diphenylphosphino)ferrocenyl]phenylmethylamine

E.e. >98%

[α]_D²⁵ = -330 (c 0.20, CHCl₃)

Source of chirality: (R)-1-[(S)-2-(diphenylphosphino)ferrocenyl]phenylmethylamine

Absolute configuration: central chirality: R,
planar chirality: S




(R)-N-(Dimethylaminoethylene)-1-[(S)-2-(diphenylphosphino)ferrocenyl]ethylamine

E.e. >98%

[α]_D²⁵ = -402 (c 0.10, CHCl₃)

Source of chirality: (R)-1-[(S)-2-(diphenylphosphino)ferrocenyl]ethylamine

Absolute configuration: central chirality: R,
planar chirality: S




(*R*)-*N*-(Dimethylaminoethylene)-1-[(*S*)-2-(diphenylphosphino)ferrocenyl]propylamine

E.e. >98%

$[\alpha]_D^{25} = -431$ (*c* 0.10, CHCl₃)

Source of chirality: (*R*)-1-[(*S*)-2-(diphenylphosphino)ferrocenyl]propylamine

Absolute configuration: central chirality: *R*,
planar chirality: *S*




(*R*)-*N*-(Dimethylaminoethylene)-1-[(*S*)-2-(diphenylphosphino)ferrocenyl]phenylmethylamine

E.e. >98%

$[\alpha]_D^{25} = -345$ (*c* 0.20, CHCl₃)

Source of chirality: (*R*)-1-[(*S*)-2-(diphenylphosphino)ferrocenyl]phenylmethyl

Absolute configuration: central chirality: *R*,
planar chirality: *S*




(*R*)-*N*-[(1-Piperidino)methylene]-1-[(*S*)-2-(diphenylphosphino)ferrocenyl]ethylamine

E.e. >98%

$[\alpha]_D^{25} = -470$ (*c* 0.10, CHCl₃)

Source of chirality: (*R*)-*N*-(dimethylaminomethylene)-1-[(*S*)-2-(diphenylphosphino)ferrocenyl]ethylamine

Absolute configuration: central chirality: *R*,
planar chirality: *S*





(*R*)-*N*-[(4-Morpholino)methylene]-1-[(*S*)-2-(diphenylphosphino)ferrocenyl]ethylamine

E.e. >98%

$[\alpha]_D^{25} = -482$ (*c* 0.11, CHCl₃)

Source of chirality: (*R*)-*N*-(dimethylaminomethylene)-1-[(*S*)-2-(diphenylphosphino)ferrocenyl]ethylamine

Absolute configuration: central chirality: *R*,
planar chirality: *S*




(S)-1-[(R)-2-Trimethylsilyl-(S)-5-(diphenylphosphino)ferrocenyl]ethylamine

E.e. >98%

[α]_D²⁵ = -342 (*c* 0.10, CHCl₃)

Source of chirality: (S)-*N,N*-dimethyl-1-[*(R)*-2-trimethylsilyl-(S)-5-(diphenylphosphino)ferrocenyl]-ethylamine

Absolute configuration: central chirality: *S*, planar chirality: *R*, planar chirality: *S*




(S)-1-[(S)-2-(Diphenylphosphino)ferrocenyl]ethylamine

E.e. >98%

[α]_D²⁵ = -341 (*c* 0.11, CHCl₃)

Source of chirality: (S)-1-[(*R*)-2-trimethylsilyl-(S)-5-(diphenylphosphino)ferrocenyl]ethylamine

Absolute configuration: central chirality: *S*, planar chirality: *R*, planar chirality: *S*




(S)-*N*-(Dimethylaminoethylene)-1-[(*S*)-2-(diphenylphosphino)ferrocenyl]ethylamine

E.e. >98%

[α]_D²⁵ = -161 (*c* 0.19, MeOH)

Source of chirality: (S)-1-[(*S*)-2-(diphenylphosphino)ferrocenyl]ethylamine

Absolute configuration: central chirality: *S*, planar chirality: *S*




(S)-*N*-(Dimethylaminoethylene)-1-[(*S*)-2-(diphenylphosphino)ferrocenyl]ethylamine

E.e. >98%

[α]_D²⁵ = -142 (*c* 0.28, MeOH)

Source of chirality: (S)-1-[(*S*)-2-(diphenylphosphino)ferrocenyl]ethylamine

Absolute configuration: central chirality: *S*, planar chirality: *S*


 $C_{20}H_{23}NO_4$

(2S)-2-Benzylcarbamoyl-4-phenylbutyric acid ethyl ester

E.e. >98%

 $[\alpha]_D = +25.1$ (*c* 1.08, CHCl₃)


Source of chirality: L-homophenylalanine ethyl ester

Absolute configuration: 2*S* $C_{19}H_{22}N_2O_4$ (1*S*)-(1-Methoxycarbamoyl-3-phenylpropyl)carbamic acid benzyl ester

E.e. >98%

 $[\alpha]_D = -29.5$ (*c* 1.03, CHCl₃)


Source of chirality: L-homophenylalanine ethyl ester

Absolute configuration: 1*S* $C_{19}H_{20}N_2O_4$ (3*S*)-(1-Methoxy-2-oxo-2,3,4,5-tetrahydro-1*H*-benzo[b]azepin-3-yl)carbamic acid benzyl ester

E.e. >98%

 $[\alpha]_D = -120.7$ (*c* 1.03, CHCl₃)

Source of chirality: L-homophenylalanine ethyl ester


Absolute configuration: 3*S* $C_{10}H_{12}N_2O$ (3*S*)-3-Amino-1,3,4,5-tetrahydrobenzo[b]azepin-2-one

E.e. >98%

 $[\alpha]_D = -447.0$ (*c* 1.02, CH₃OH)

Source of chirality: L-homophenylalanine ethyl ester


Absolute configuration: 3*S*

 $C_{19}H_{22}O_3S$ 5-Benzyl-1-(*S_R*)-(4-methylphenylsulfinyl)-(2*R*,3*E*)-penten-2-ol

De >95%

 $[\alpha]_D^{24} = 118.9$ (*c* 0.75, CHCl₃)


Source of chirality: asymmetric synthesis

Absolute configuration: (*R_S,2*R**) $C_{19}H_{23}BrO_4S$ 5-Benzyl-4-bromo-1-(*S_S*)-(4-methylphenylsulfinyl)-(2*R*,3*R*,4*S*)-pentane-2,3-diol

De >95%

 $[\alpha]_D^{24} = -129.5$ (*c* 1.0, CHCl₃)


Source of chirality: asymmetric synthesis

Absolute configuration: (*S_S,2*R*,3*R*,4*S**) $C_{22}H_{29}BrO_4S$ 4-[2-Benzyl-1-bromo-(1*S*)-ethyl]-2,2-dimethyl-5-(*S_S*)-(4-methylphenylsulfinylmethyl)-(4*R*,5*R*)-1,3-dioxolane

De >95%

 $[\alpha]_D^{24} = -152.4$ (*c* 1.0, CHCl₃)

Source of chirality: asymmetric synthesis


Absolute configuration: (*S_S,1*S*,4*R*,5*R**) $C_{22}H_{29}N_3O_4S$ 4-[1-Azido-2-benzyl-1*R*-ethyl]-2,2-dimethyl-5-(*S_S*)-(4-methylphenylsulfinylmethyl)-(4*S*,5*R*)-1,3-dioxolane

De >95%

 $[\alpha]_D^{24} = -49.5$ (*c* 0.65, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (*S_S,1*R*,4*S*,5*R**)




2-Azido-2-[2,2-dimethyl-5-[1-(4-methylphenylsulfanyl)-(E)-3-tetradecenyl]-4S,5R)-1,3-dioxolan-4-yl]ethylbenzylether

De >95%

 $[\alpha]_D^{24} = 13.1$ (*c* 0.2, CHCl₃)


Source of chirality: asymmetric synthesis

Absolute configuration: (4*S*,5*R*)2-(*N*-tert-Butoxycarbonyl)amino-2-(2,2-dimethyl-5-tetradecyl-(4*S*,5*R*)-1,3-dioxolan-4-yl)-1-ethanol

De >95%

 $[\alpha]_D^{24} = -9.1$ (*c* 0.6, CHCl₃)


Source of chirality: asymmetric synthesis

Absolute configuration: (4*S*,5*R*)1-[5-[1-Azido-2-benzyloxy-(1*R*)-ethyl]-2,2-dimethyl-5-[1-(4-methylphenylsulfonyl)-(E)-3-tetradecenyl]-4*S*,5*R*)-1,3-dioxolane

De >95%

 $[\alpha]_D^{24} = -12.7$ (*c* 1.6, CHCl₃)

Source of chirality: asymmetric synthesis







Absolute configuration: (1*R*,4*S*,5*R*)2-(*N*-tert-Butoxycarbonyl)amino-2-{2,2-dimethyl-5-[1-(4-methylphenylsulfonyl)tetracetyl]-4*S*,5*S*)-1,3-dioxolan-4-yl}-1-ethanol

De >95%


 $[\alpha]_D^{24} = -3.4$ (*c* 2.4, CHCl₃)

Source of chirality: asymmetric synthesis

Absolute configuration: (4*S*,5*S*)


 $[\alpha]_D^{20} = +91.2$ (*c* 1.0, CHCl₃)
Source of chirality: (*S*)-malic acidAbsolute configuration: (4*S*,5*R*)(4*S*,5*R*)-4-Benzyl-5-methyl-2-pyrrolidinone(4*S*,5*R*)-4-Benzyl-5-methyl-2-pyrrolidinone
 $[\alpha]_D^{20} = +60.5$ (*c* 1.0, CHCl₃)
Source of chirality: (*S*)-malic acidAbsolute configuration: (4*S*,5*R*)(4*S*,5*R*)-4-Benzyl-1-(*tert*-butyloxycarbonyl)-5-methyl-2-pyrrolidinone
 $[\alpha]_D^{20} = -21.1$ (*c* 1.1, CHCl₃)
Source of chirality: (*S*)-malic acidAbsolute configuration: (4*S*,5*R*)(4*S*,5*R*)-4-Hydroxy-1-(*tert*-butyloxycarbonyl)-5-methyl-2-pyrrolidinone
 $[\alpha]_D^{20} = -48.4$ (*c* 0.7, MeOH)


 $[\alpha]_D^{20} = -36.4$ (*c* 1.0, CHCl₃)
Source of chirality: (*S*)-malic acidAbsolute configuration: (4*S*,5*R*)




$[\alpha]_D^{20} = +10.0$ (*c* 0.58, MeOH)

Source of chirality: (*S*)-malic acid

Absolute configuration: (3*S*,4*R*)




(3*S*,4*R*)-4-(*tert*-Butyloxycarbonylaminooxy)-3-hydroxypentanoic acid ethyl ester




$[\alpha]_D^{20} = +33.5$ (*c* 2.1, CHCl₃)

Source of chirality: (*S*)-malic acid

Absolute configuration: (4*S*,5*R*)




(4*S*,5*R*)-4-Benzyl-5-(cyclohexylmethyl)-1-(4-methoxybenzyl)-2-pyrrolidinone




$[\alpha]_D^{20} = +50.0$ (*c* 1.0, CHCl₃)

Source of chirality: (*S*)-malic acid

Absolute configuration: (4*S*,5*R*)




(4*S*,5*R*)-4-Benzyl-5-(cyclohexylmethyl)-2-pyrrolidinone










$[\alpha]_D^{20} = -34.8$ (*c* 0.9, CHCl₃)


Source of chirality: (*S*)-malic acid

Absolute configuration: (4*S*,5*R*)



(4*S*,5*R*)-4-Benzyl-5-(tert-butyloxycarbonyl)-1-(tert-butyloxycarbonyl)-2-pyrrolidinone


 $[\alpha]_D^{20} = -48.4$ (*c* 1.1, MeOH)Source of chirality: (*S*)-malic acidAbsolute configuration: (4*S*,5*R*)(4*S*,5*R*)-4-Hydroxy-1-(*tert*-butyloxycarbonyl)-5-(cyclohexylmethyl)-2-pyrrolidinone $[\alpha]_D^{20} = +21.5$ (*c* 1.0, MeOH)Source of chirality: (*S*)-malic acidAbsolute configuration: (3*S*,4*R*)(3*S*,4*R*)-4-[(*tert*-Butyloxycarbonyl)amino]-5-cyclohexyl-3-hydroxypentanoic acid ethyl ester $[\alpha]_D^{20} = -42.1$ (*c* 1.2, CHCl₃)Source of chirality: (*S*)-malic acidAbsolute configuration: (*S*)(S)-1-Benzyl-3-(*tert*-butyldimethylsilyloxy)pyrrolidine-2,5-dione[(*S*)- α -(Diphenylphosphino)-(methylene-phenyl-amino)]ferroceneE.e. >98% (by ¹H NMR) $[\alpha]_D^{20} = 134$ (*c* 0.50, CH₂Cl₂)Source of chirality: (*S*)-(-)-1,2,4-butanetriolAbsolute configuration: *S_P*



C₃₀H₂₆NPF_e
[(S)- α -(Diphenylphosphino)-(methylene-benzyl-amino)]ferrocene

E.e. >98% (by ¹H NMR)[α]_D²⁰ = 342 (*c* 0.50, CH₂Cl₂)


Source of chirality: (S)-(-)-1,2,4-butanetriol

Absolute configuration: S_P

C₂₇H₂₈NPF_e
[(S)- α -(Diphenylphosphino)-(methylene-*tert*-butyl-amino)]ferrocene

E.e. >98% (by ¹H NMR)[α]_D²⁰ = 242 (*c* 0.50, CH₂Cl₂)


Source of chirality: (S)-(-)-1,2,4-butanetriol

Absolute configuration: S_P

C₃₆H₃₀NPF_e
[(S)- α -(Diphenylphosphino)-(methylene-diphenylmethyl-amino)]ferrocene

E.e. >98% (by ¹H NMR)[α]_D²⁰ = 174 (*c* 0.50, CH₂Cl₂)

Source of chirality: (S)-(-)-1,2,4-butanetriol








Absolute configuration: S_P

C₂₇H₁₉O₃NPMn
Tricarbonyl[(S)- α -(diphenylphosphino)-(methylene-phenyl-amino)cyclopentadienyl]manganese

E.e. >98% (by ¹H NMR)[α]_D²⁰ = -390 (*c* 0.25, CH₂Cl₂)

Source of chirality: (S)-(-)-1,2,4-butanetriol

Absolute configuration: S_P

Tricarbonyl[(S)- α -(diphenylphosphino)-(methylene-benzyl-amino)cyclopentadienyl]manganeseE.e. >98% (by 1H NMR) $[\alpha]_D^{20} = -590$ (*c* 0.25, CH_2Cl_2)Source of chirality: (*S*)-(-)-1,2,4-butanetriolAbsolute configuration: *S_P*Tricarbonyl[(S)- α -(diphenylphosphino)-(methylene-diphenylmethyl-amino)cyclopentadienyl]manganeseE.e. >98% (by 1H NMR) $[\alpha]_D^{20} = -253$ (*c* 0.50, CH_2Cl_2)Source of chirality: (*S*)-(-)-1,2,4-butanetriolAbsolute configuration: *S_P*Dicarbonyl(triphenylphosphine)[(S)- α -(diphenylphosphino)-formyl-cyclopentadienyl]manganeseE.e. >98% (by 1H NMR) $[\alpha]_D^{20} = -224$ (*c* 0.50, CH_2Cl_2)Source of chirality: (*S*)-(-)-1,2,4-butanetriolAbsolute configuration: *S_P*Dicarbonyl(triphenylphosphine)[(S)- α -(diphenylphosphino)-(methylene-diphenylmethyl-amino)cyclopentadienyl]manganeseE.e. >98% (by 1H NMR) $[\alpha]_D^{20} = -608$ (*c* 0.25, CH_2Cl_2)Source of chirality: (*S*)-(-)-1,2,4-butanetriolAbsolute configuration: *S_P*